Cobra and CPI enter £1.8 million project
London | 29 February 2016

Cobra Biologics and the Centre for Process Innovation (CPI) have collaborated on a £1.8 million project to develop a manufacturing platform for adeno-associated virus (AAV) to support gene therapy and regenerative medicine.

Innovate UK is funding the project with £1.4 million via its 2015 competition for the development of regenerative medicines and cell therapies.

Cobra and CPI’s collaboration will focus on AAV vectors that serve as the current delivery vehicle of choice for gene therapy treatments.

They will allow a scalable and flexible manufacturing process to be developed to produce, purify and characterise a range of AAV vectors.

The project is one of five that comprise an £8 million investment into collaborative R&D projects that address critical challenges faced by UK companies developing clinical treatments and commercial products.

Dr Fergal O’Brien, director of biologics at CPI, said: “CPI is delighted to be collaborating with Cobra. We see this project as a key enabler in meeting the current and future needs of the biologics industry and are delighted to be supporting a leading UK company in this sector.”

Author: Tammy Facey

More IPPro Life Sciences | latest news
AstraZeneca enters China with Plendil
Hogan Lovells boosts capabilities in Japan
Morgan Lewis bags four from K&L Gates
Cobra and CPI enter £1.8 million project
Doctors Without Borders urges lower vaccine prices
IPPro Life Sciences


Copyright (C) 2013 Black Knight Media Ltd. All rights reserved. No reproduction without prior authorization